RESUMEN
We discuss the design, modelling, fabrication and characterisation of an integrated tuneable birefringent waveguide for quantum cascade lasers. We have fabricated quantum cascade lasers operating at wavelengths around 4450 nm that include polarisation mode converters and a differential phase shift section. We employed below laser threshold electroluminescence to investigate the single pass operation of the integrated device. We use a theory based on the electro-optic properties of birefringence in quantum cascade laser waveguides combined with a Jones matrix based description to gain an understanding of the electroluminescence results. With the quantum cascade lasers operating above threshold we demonstrated polarisation control of the output.
RESUMEN
We discuss the design, fabrication and characterization of waveguide polarization mode converters for quantum cascade lasers operating at 4.6 µm. We have fabricated a quantum cascade laser with integrated polarization mode converter that emits light of 69% Transverse Electrical (TE) polarization from one facet and 100% Transverse Magnetic (TM) polarization from the other facet.
Asunto(s)
Antimaláricos/efectos adversos , Artemisininas , Malaria Falciparum/tratamiento farmacológico , Mefloquina/efectos adversos , Vómitos/inducido químicamente , Acetaminofén/uso terapéutico , Adolescente , Analgésicos no Narcóticos/uso terapéutico , Artesunato , Niño , Preescolar , Fiebre/tratamiento farmacológico , Humanos , Sesquiterpenos/uso terapéutico , TailandiaRESUMEN
An open, randomized comparison of artemether-benflumetol (CGP 56 697; Novartis) with artesunate-mefloquine was conducted in 617 patients with acute uncomplicated multidrug-resistant falciparum malaria on the western border of Thailand. Both treatments rapidly and reliably cleared fever and parasitemia, and there was no significant difference in the initial therapeutic response parameters. Parasite genotyping was used to distinguish recrudescences from new infections. The 63-day cure rate for artesunate-mefloquine (94%) was significantly higher than the cure rate for artemether-benflumetol (81%) (P < 0.001). Both regimens were well tolerated. Nausea, vomiting, dizziness, sleep disorders, and other neurological side effects were between two and four times more common in the artesunate-mefloquine group than in the artemether-benflumetol group (P < 0.001). Artemether-benflumetol is effective and very well tolerated in the treatment of multidrug-resistant falciparum malaria. A higher dose than that used in the present study may improve efficacy.
